SGD Pharma acquires Italy’s Alphial to strengthen global tubular glass capabilities

ITALY – SGD Pharma, a leading global provider of pharmaceutical glass packaging, has signed an agreement with Italian private equity firm Entangled Capital to acquire Alphial S.r.l., a specialist manufacturer of tubular vials and ampoules headquartered in Italy.

The transaction, subject to Italian FDI clearance, marks a significant step in SGD Pharma’s strategy to expand its tubular glass operations and strengthen its presence in Europe.

Founded in Italy, Alphial operates four manufacturing sites and employs more than 220 people. The company specializes in tubular glass converting, producing ampoules, vials, and ready-to-use (RTU) products for the pharmaceutical sector.

The acquisition will enable SGD Pharma to broaden its product portfolio and extend its reach across Europe, complementing its existing operations.

“This acquisition represents a significant milestone in our growth strategy and will enable us to better serve our clients with an expanded portfolio of services and solutions,” said Olivier Rousseau, CEO of SGD Pharma.

“We are excited to welcome Alphial S.r.l. to the SGD Pharma family.”

The deal follows SGD Pharma’s joint venture with Corning, announced two years ago, to establish a new pharmaceutical tubing facility near its Vemula plant in India.

That project, now nearing completion, aims to secure supply chains, reduce carbon footprint, and deliver consistent quality.

Together with the Alphial acquisition, these initiatives reflect SGD Pharma’s commitment to building a resilient, global tubular glass manufacturing network.

Commenting on the move, Fabio Invernizzi, General Manager of SGD Pharma’s West Business Unit, said, “We have been investing heavily in the development of tubular glass and RTU over the last years. Together with the Alphial team, I am truly excited to accelerate this momentum.”

Valerio Marchi, CEO of Alphial S.r.l., added, “We are pleased to join the SGD Pharma Group. SGD Pharma will help Alphial grow, enhance its offering, and improve industrial performance.”

The integration process will begin following regulatory clearance and closing. Both companies have committed to ensuring a seamless transition for employees, customers, and partners.

With demand for high-quality pharmaceutical glass packaging continuing to rise worldwide, the acquisition positions SGD Pharma to deliver greater value to its global customer base while reinforcing its role as a leading supplier in both tubular and molded glass solutions.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE